2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1665

Glucocorticoids in Incident ANCA-Associated Vasculitis (AAV) Patients – A Study of Routine Clinical Practice in the EU Demonstrates Prolonged Use and Temporal Relationship to Adverse Events and Infections
Abstract Number: 1688

Glucocorticoids Plus Rituximab versus Glucocorticoids Plus Placebo in Non-infectious Active Mixed Cryoglobulinemia Vasculitis: Results of a Placebo-Controlled Randomized Trial
Abstract Number: 2562

Glucocorticosteroid Usage and Major Organ Damage in Patients with Systemic Lupus Erythematosus – Meta-analyses of Observational Studies Published Between 1979 and 2018
Abstract Number: 1766

GM-CSF Is a Pro-Inflammatory Cytokine in Experimental Vasculitis of Medium and Large Arteries
Abstract Number: 2689

GM-CSF Pathway Signature Identified in Temporal Artery Biopsies of Patients with Giant Cell Arteritis
Abstract Number: 2876

Go-Dact: A Phase 3b Randomized Double-Blind Placebo-Controled Proof-Of-Concept Trial, of Golimumab Plus Methotrexate (MTX) versus MTX Monotherapy, in Improving Dactylitis, in MTX Naïve Psoriatic Arthritis Patients
Abstract Number: 1446

Golimumab as First, Second or at Least Third Biologic Agent in Patients with Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) or Ankylosing Spondylitis (AS) – Post Hoc Analysis of a Non-Interventional Study in Germany
Abstract Number: 1477

Golimumab Improves Direct Costs of Healthcare Utilization and Indirect Costs Within Patients with RA, PsA, and as – Analysis of a Non-Interventional Study in Germany
Abstract Number: 1087

Golimumab Improves Work Productivity and Activity and Quality of Life in Patients with Rheumatoid Arthritis (RA), Ankylosing Spondylitis (AS) and Psoriatic Arthritis (PsA): Final Results from a Non-Interventional Study in Germany (GO-ART)
Abstract Number: 1499

Golimumab Persistence in Biologic Naive and Non-Naive Patients with Axial Spondyloarthritis: Results of the GO PRACTICE Study
Abstract Number: 228

Good Pain, Bad Pain: Illness Perception and Physicians Attitude Towards Rheumatoid Arthritis and Fibromyalgia Patients
Abstract Number: 1183

Gout and Serum Urate Levels Are Associated with Lumbar Spine Monosodium Urate Deposition and Chronic Low Back Pain: A Dual-Energy CT Study
Abstract Number: 356

Gout Flares Become Infrequent During a Treat-to-target Strategy over One Year: Data from the NOR-Gout Study
Abstract Number: 337

Gout in the US: Significant Association with Cardiovascular and Renal Disease Hospitalizations – A Nationwide Study
Abstract Number: 331

Gout Management in the Medical Community: A Claims-Based Analysis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].